AMPH Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Amphastar Pharmaceuticals (NASDAQ: AMPH)
›
Amphastar Pharmaceuticals (NASDAQ: AMPH) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 1,976 employees.
The shares were at 28.11 USD on 19 November 2026, up 11.3% over 52 weeks. Its 52-week range is 16.65 USD to 30.79 USD: the price is 8.7% below the high and 68.8% above the low.
At a market capitalisation of 1.20B USD, it trades at 12.9 times trailing earnings and 8.4 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 48% for AMPH.
Amphastar Pharmaceuticals reports return on equity of 12.4%, an operating margin of 18.7% and revenue up 8.2% year over year.
Its debt exceeds its cash by 461.06M USD, a debt-to-equity ratio of 0.83. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 6 analysts cover the stock, with an average rating of Hold; their mean price target of 24.50 USD is 12.8% below the current price. The next earnings report is expected on 25 February 2027.